217 related articles for article (PubMed ID: 31024558)
1. Adeno-Associated Virus as an Effective Malaria Booster Vaccine Following Adenovirus Priming.
Yusuf Y; Yoshii T; Iyori M; Yoshida K; Mizukami H; Fukumoto S; Yamamoto DS; Alam A; Emran TB; Amelia F; Islam A; Otsuka H; Takashima E; Tsuboi T; Yoshida S
Front Immunol; 2019; 10():730. PubMed ID: 31024558
[TBL] [Abstract][Full Text] [Related]
2. Liver-Directed AAV8 Booster Vaccine Expressing
Shahnaij M; Iyori M; Mizukami H; Kajino M; Yamagoshi I; Syafira I; Yusuf Y; Fujiwara K; Yamamoto DS; Kato H; Ohno N; Yoshida S
Front Immunol; 2021; 12():612910. PubMed ID: 34248928
[TBL] [Abstract][Full Text] [Related]
3. A Viral-Vectored Multi-Stage Malaria Vaccine Regimen With Protective and Transmission-Blocking Efficacies.
Yusuf Y; Yoshii T; Iyori M; Mizukami H; Fukumoto S; Yamamoto DS; Emran TB; Amelia F; Islam A; Syafira I; Yoshida S
Front Immunol; 2019; 10():2412. PubMed ID: 31681301
[TBL] [Abstract][Full Text] [Related]
4. A two-dose viral-vectored
Yamamoto Y; Fabbri C; Okuhara D; Takagi R; Kawabata Y; Katayama T; Iyori M; Hasyim AA; Sakamoto A; Mizukami H; Shida H; Lopes S; Yoshida S
Front Immunol; 2024; 15():1372584. PubMed ID: 38745665
[TBL] [Abstract][Full Text] [Related]
5. Adeno-associated virus-based malaria booster vaccine following attenuated replication-competent vaccinia virus LC16m8Δ priming.
Hasyim AA; Iyori M; Mizuno T; Abe YI; Yamagoshi I; Yusuf Y; Syafira I; Sakamoto A; Yamamoto Y; Mizukami H; Shida H; Yoshida S
Parasitol Int; 2023 Feb; 92():102652. PubMed ID: 36007703
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model.
Yoshida K; Iyori M; Blagborough AM; Salman AM; Dulal P; Sala KA; Yamamoto DS; Khan SM; Janse CJ; Biswas S; Yoshii T; Yusuf Y; Tokoro M; Hill AVS; Yoshida S
Sci Rep; 2018 Mar; 8(1):3896. PubMed ID: 29497047
[TBL] [Abstract][Full Text] [Related]
7. Sterile protection and transmission blockade by a multistage anti-malarial vaccine in the pre-clinical study.
Iyori M; Blagborough AM; Mizuno T; Abe YI; Nagaoka M; Hori N; Yamagoshi I; Da DF; Gregory WF; Hasyim AA; Yamamoto Y; Sakamoto A; Yoshida K; Mizukami H; Shida H; Yoshida S
Front Immunol; 2022; 13():1005476. PubMed ID: 36248835
[TBL] [Abstract][Full Text] [Related]
8. New adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit Plasmodium falciparum transmission.
McGuire KA; Miura K; Wiethoff CM; Williamson KC
Malar J; 2017 Jun; 16(1):254. PubMed ID: 28619071
[TBL] [Abstract][Full Text] [Related]
9. A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activity.
Goodman AL; Blagborough AM; Biswas S; Wu Y; Hill AV; Sinden RE; Draper SJ
PLoS One; 2011; 6(12):e29428. PubMed ID: 22216279
[TBL] [Abstract][Full Text] [Related]
10. Enhanced immunity to Plasmodium falciparum circumsporozoite protein (PfCSP) by using Salmonella enterica serovar Typhi expressing PfCSP and a PfCSP-encoding DNA vaccine in a heterologous prime-boost strategy.
Chinchilla M; Pasetti MF; Medina-Moreno S; Wang JY; Gomez-Duarte OG; Stout R; Levine MM; Galen JE
Infect Immun; 2007 Aug; 75(8):3769-79. PubMed ID: 17502396
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine.
McCoy ME; Golden HE; Doll TA; Yang Y; Kaba SA; Zou X; Gerbasi VR; Burkhard P; Lanar DE
Malar J; 2013 Apr; 12():136. PubMed ID: 23607541
[TBL] [Abstract][Full Text] [Related]
12. A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults.
Sklar MJ; Maiolatesi S; Patterson N; Sedegah M; Limbach K; Teneza-Mora N; Chuang I; Hollis-Perry KM; Banania JG; Guzman I; Ganeshan H; Reyes S; Hollingdale MR; Wong M; Lindstrom A; Reyes A; Alcorta Y; Garver L; Bankard K; Belmonte A; Belmonte M; Huang J; Gowda K; Inoue S; Velasco R; Bergmann-Leitner E; Hutter J; Lee T; Adams N; Chaudhury S; Hunt D; Tamminga C; Berrie E; Bellamy D; Bittaye M; Ewer K; Diggs C; Soisson LA; Lawrie A; Hill A; Richie TL; Villasante E; Epstein JE; Duplessis CA
PLoS One; 2021; 16(9):e0256980. PubMed ID: 34495988
[TBL] [Abstract][Full Text] [Related]
13. Poor CD4
Zaric M; Marini A; Nielsen CM; Gupta G; Mekhaiel D; Pham TP; Elias SC; Taylor IJ; de Graaf H; Payne RO; Li Y; Silk SE; Williams C; Hill AVS; Long CA; Miura K; Biswas S
Front Immunol; 2021; 12():732667. PubMed ID: 34659219
[No Abstract] [Full Text] [Related]
14. Protective antibody and CD8+ T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine.
Kaba SA; McCoy ME; Doll TA; Brando C; Guo Q; Dasgupta D; Yang Y; Mittelholzer C; Spaccapelo R; Crisanti A; Burkhard P; Lanar DE
PLoS One; 2012; 7(10):e48304. PubMed ID: 23144750
[TBL] [Abstract][Full Text] [Related]
15. Down-selecting circumsporozoite protein-based malaria vaccine: A comparison of malaria sporozoite challenge model.
Amelia F; Iyori M; Emran TB; Yamamoto DS; Genshi K; Otsuka H; Onoue Y; Yusuf Y; Islam A; Yoshida S
Parasite Immunol; 2019 May; 41(5):e12624. PubMed ID: 30883819
[TBL] [Abstract][Full Text] [Related]
16. Protective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite protein.
Iyori M; Nakaya H; Inagaki K; Pichyangkul S; Yamamoto DS; Kawasaki M; Kwak K; Mizukoshi M; Goto Y; Matsuoka H; Matsumoto M; Yoshida S
PLoS One; 2013; 8(8):e70819. PubMed ID: 23951015
[TBL] [Abstract][Full Text] [Related]
17. The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert.
Radosevic K; Rodriguez A; Lemckert AA; van der Meer M; Gillissen G; Warnar C; von Eyben R; Pau MG; Goudsmit J
Clin Vaccine Immunol; 2010 Nov; 17(11):1687-94. PubMed ID: 20826614
[TBL] [Abstract][Full Text] [Related]
18. Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations.
Coban C; Philipp MT; Purcell JE; Keister DB; Okulate M; Martin DS; Kumar N
Infect Immun; 2004 Jan; 72(1):253-9. PubMed ID: 14688103
[TBL] [Abstract][Full Text] [Related]
19. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
[TBL] [Abstract][Full Text] [Related]
20. Protective efficacy of an IL-12-expressing baculoviral malaria vaccine.
Iyori M; Blagborough AM; Sala KA; Nishiura H; Takagi K; Yoshida S
Parasite Immunol; 2017 Dec; 39(12):. PubMed ID: 29072334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
